Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
NIZATIDINE
B & S Healthcare
150 Milligram
Capsules Hard
2007-05-18
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PPA1328/071/001 Case No: 2029763 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to B & S HEALTHCARE UNIT 4, BRADFIELD ROAD, RUISLIP, MIDDLESEX, HA4 0NU, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product AXID 150MG HARD CAPSULES The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 18/05/2007 until 17/05/2012. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 26/09/2007_ _CRN 2029763_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Axid 150mg Hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 150mg of nizatidine. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard _Product imported from the UK:_ Hard gelatin capsules with dark yellow caps and pale yellow bodies, coded FLYNN 3144, containing an off-white granular powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of the following diseases where reduction of gastric acid is indicated: Duodenal ulcer, Benign gastric ulcer, Prevention of duodenal or benign gastric ulcer recurrence, Gastric and Read the complete document